Clinical Research Services
Experience Is The Difference
Cytel Clinical Research Services combines decades of biostatistical advancements, clinical software programming, operations know-how and deep regulatory familiarity.
We focus on developing and deploying technology that enables sponsors to markedly improve their clinical efficiencies and outcomes.
Built on collaborations with industry, academia and international regulators, our trial design, analysis and data management strategies are rigrously precise and proven to speed critical processes.
In fact, all 25 of the leading global biopharmaceuticals use Cytel technology in their clinical trials.
Clinical Research Capabilities Overview .pdf
Clinical Services Client Work
“Working together with Cytel allowed our team to move from research to reality with swiftness not possible without Cytel.
We now have tools to help guide our innovative trial design decision-making much more efficiently and knowledgeably.
”
Read the Dose-responsive Simulation Software Project Profile
Joseph Heyse
Vice President, Early Stage Biostatistics
Merck Research Labs
“We want to acknowledge Cytel’s pivotal role. Without Cytel we would not have got this far. You have been very service-oriented and responsive.”
Read Profile on Adaptive Combined Phase 2 & 3 Trial for HIV Related Disease
Scott Harris
Chief Medical Officer
Napo Pharmaceuticals
“Cytel’s work on the trial design, simulation and FDA discussions was instrumental in obtaining regulatory acceptance for the proposed methodology in implementing a groundbreaking adaptive trial.”
Read the Population Selection/Enrichment Cardiology Treatment Project Profile
Simona Skerjanec,
Vice President,
Medical Science
The Medicines Company
“Cytel's innovative, yet practical adaptive design provided multiple favorable scenarios that allowed us to proceed with a pivotal study based sample size re-estimation.
Difficult to imagine our going forward with traditional methods alone.
”
Read the Adaptive Approaches in Oncology: When a Patient Population Increase is the Best Bet
Steven B. Ketchum,
Senior Vice President, Research & Development
Sunesis Pharmaceuticals